Skip to content
2000
Volume 32, Issue 35
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

The PANoptosis pathway is a recently identified mechanism of cellular death that involves the interaction and synchronization among cellular pyroptosis, apoptosis, and necrosis. More and more evidence suggests that PANoptosis is involved in the development and treatment of cancer. However, a comprehensive understanding of the influence of PANoptosis genes on prognostic value, tumor microenvironment characteristics, and therapeutic outcomes in patients with ovarian cancer (OC) remains incomplete.

Objective

The present work was designed to devise a PANoptosis signature for OC prognosis and explore its potential molecular function.

Methods

For this study, we obtained RNA sequencing and clinical data for ovarian cancer from the Cancer Genome Atlas (TCGA) and the GSE32062 cohort. Somatic variants of PANoptosis-related genes (PRGs) in OC were analyzed using GSCA. TCGA-OC and GSE32062 were used to construct training and validation cohorts for the model. Differential expression and correlation analyses were performed following the screening of genes with prognostic ability using univariate Cox analysis. Least Absolute Shrinkage and Selection Operator (LASSO) regression was performed to construct PRG signature based on genes that were differentially expressed and correlated with prognosis. CIBERSORT and ESTIMATE were used to analyze the relationship between the PRGs signature and immune infiltration. TIDE was used to analyze the relationship between the PRG signature and immune checkpoint genes. OncoPredict was used to analyze the relationship between the PRG signature and the drug sensitivity. Quantitative real-time PCR (qRT-PCR) was used to validate the expression of PRGs in OC.

Results

The PRG signature was constructed using three prognostic genes (AIM2, APAF1, and ZBP1) in both TCGA-OC. The results showed that the PRGs signature had an AUC of 0.521, 0.546, and 0.598 in TCGA-OC and 0.620, 0.586, and 0.579 in GSE32062 to predict to predict OS at 1-, 3-, and 5-year intervals. Furthermore, a higher PRG signature risk score was significantly associated with shorter OS (HR = 1.693, 95% CI: 1.303 - 2.202, = 8.34 × 10-5 in TCGA-OC and HR = 1.63, 95% CI: 1.13 - 2.35, = 0.009 in GSE32062). The risk score was identified as the independent prognostic factor for OC. Patients categorized according to their risk score exhibited notable variations in immune status, response to immunotherapy, and sensitivity to drugs. AIM2, APAF1, and ZBP1 were significantly aberrantly expressed in OC cell lines.

Conclusion

The PRG signature has the potential to serve as a prognostic predictor for OC and to provide new insights into OC treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673314864240829064622
2024-09-06
2025-11-01

  • From This Site

    /content/journals/cmc/10.2174/0109298673314864240829064622
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ChengZ. ChenY. HuangH. Identification and validation of a novel prognostic signature based on ferroptosis-related genes in ovarian cancer.Vaccines (Basel)202311220510.3390/vaccines1102020536851083
     [Google Scholar]
  2. EbellM.H. CulpM.B. RadkeT.J. A systematic review of symptoms for the diagnosis of ovarian cancer.Am. J. Prev. Med.201650338439410.1016/j.amepre.2015.09.02326541098
     [Google Scholar]
  3. WilsonM.K. Pujade-LauraineE. AokiD. MirzaM.R. LorussoD. OzaA.M. du BoisA. VergoteI. ReussA. BaconM. FriedlanderM. Gallardo-RinconD. JolyF. ChangS.J. FerreroA.M. EdmondsonR.J. WimbergerP. MaenpaaJ. GaffneyD. ZangR. OkamotoA. StuartG. OchiaiK. participants of the Fifth Ovarian Cancer Consensus Conference Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease.Ann. Oncol.201728472773210.1093/annonc/mdw66327993805
     [Google Scholar]
  4. ZhangL. ZhaoW. HuangJ. LiF. ShengJ. SongH. ChenY. Development of a dendritic cell/tumor cell fusion cell membrane nano-vaccine for the treatment of ovarian cancer.Front. Immunol.20221382826310.3389/fimmu.2022.82826335251013
     [Google Scholar]
  5. KossaïM. LearyA. ScoazecJ.Y. GenestieC. Ovarian cancer: A heterogeneous disease.Pathobiology2018851-2414910.1159/00047900629020678
     [Google Scholar]
  6. KarkiR. SharmaB.R. LeeE. BanothB. MalireddiR.K.S. SamirP. TuladharS. MummareddyH. BurtonA.R. VogelP. KannegantiT.D. Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer.JCI Insight2020512e13672010.1172/jci.insight.13672032554929
     [Google Scholar]
  7. LeeS. KarkiR. WangY. NguyenL.N. KalathurR.C. KannegantiT.D. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence.Nature2021597787641541910.1038/s41586‑021‑03875‑834471287
     [Google Scholar]
  8. KarkiR. SundaramB. SharmaB.R. LeeS. MalireddiR.K.S. NguyenL.N. ChristgenS. ZhengM. WangY. SamirP. NealeG. VogelP. KannegantiT.D. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis.Cell Rep.202137310985810.1016/j.celrep.2021.10985834686350
     [Google Scholar]
  9. MalireddiR.K.S. KarkiR. SundaramB. KancharanaB. LeeS. SamirP. KannegantiT.D. Inflammatory cell death, panoptosis, mediated by cytokines in diverse cancer lineages inhibits tumor growth.Immunohorizons20215756858010.4049/immunohorizons.210005934290111
     [Google Scholar]
  10. WangY. KannegantiT.D. From pyroptosis, apoptosis and necroptosis to PANoptosis: A mechanistic compendium of programmed cell death pathways.Comput. Struct. Biotechnol. J.2021194641465710.1016/j.csbj.2021.07.03834504660
     [Google Scholar]
  11. ChenL. GeM. MoS. ShiM. ZhangJ. LiuJ. Construction of a new ferroptosis-related prognosis model for survival prediction in colorectal cancer.Curr. Med. Chem.202438362684
     [Google Scholar]
  12. WangT. ChenP. LiT. LiJ. ZhaoD. MengF. ZhaoY. ZhengZ. LiuX. A five-gene signature based on microrna for predicting prognosis and immunotherapy in stomach adenocarcinoma.Curr. Med. Chem.202431172378239910.2174/010929867328163123112705101738310388
     [Google Scholar]
  13. ChenJ. TangH. LiT. JiangK. ZhongH. WuY. HeJ. LiD. LiM. CaiX. Comprehensive analysis of the expression, prognosis, and biological significance of OVOLs in breast cancer.Int. J. Gen. Med.2021143951396010.2147/IJGM.S32640234345183
     [Google Scholar]
  14. LinZ. HuangW. YiY. LiD. XieZ. LiZ. YeM. LncRNA ADAMTS9-AS2 is a prognostic biomarker and correlated with immune infiltrates in lung adenocarcinoma.Int. J. Gen. Med.2021148541855510.2147/IJGM.S34068334849000
     [Google Scholar]
  15. LaoY. LiT. XieX. ChenK. LiM. HuangL. MiR-195-3p is a novel prognostic biomarker associated with immune infiltrates of lung adenocarcinoma.Int. J. Gen. Med.20221519120310.2147/IJGM.S35034035023957
     [Google Scholar]
  16. LiM. WangX. LiuJ. MaoX. LiD. WangZ. TangY. WuS. Identification of core prognosis-related candidate genes in chinese gastric cancer population based on integrated bioinformatics.BioMed Res. Int.2020202011410.1155/2020/885982633381592
     [Google Scholar]
  17. LuX. JingL. LiuS. WangH. ChenB. miR-149-3p is a potential prognosis biomarker and correlated with immune infiltrates in uterine corpus endometrial carcinoma.Int. J. Endocrinol.2022202211510.1155/2022/500612335719192
     [Google Scholar]
  18. LiC. LiangH. BianS. HouX. MaY. Construction of a prognosis model of the pyroptosis-related gene in multiple myeloma and screening of core genes.ACS Omega2022738346083462010.1021/acsomega.2c0421236188246
     [Google Scholar]
  19. JiangH. AwutiG. GuoX. Construction of an immunophenoscore-related signature for evaluating prognosis and immunotherapy sensitivity in ovarian cancer.ACS Omega2023836330173303110.1021/acsomega.3c0485637720747
     [Google Scholar]
  20. LiN. YuK. HuangD. ZhouH. ZengD. Identifying a novel eight-nk cell-related gene signature for ovarian cancer prognosis prediction.Curr. Med. Chem.202431121578159437650393
     [Google Scholar]
  21. LiX. LeiJ. ShiY. PengZ. GongM. ShuX. Developing a risks-core model based on angiogenesis-related lncrnas for colon adenocarcinoma prognostic prediction.Curr. Med. Chem.2024311724492466
     [Google Scholar]
  22. WangJ. ShuJ. Construction of RNA methylation modification-immune-related lncRNA molecular subtypes and prognostic scoring system in lung adenocarcinoma.Curr. Med. Chem.202431121539156037680151
     [Google Scholar]
  23. SubramanianA. TamayoP. MoothaV.K. MukherjeeS. EbertB.L. GilletteM.A. PaulovichA. PomeroyS.L. GolubT.R. LanderE.S. MesirovJ.P. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles.Proc. Natl. Acad. Sci. USA200510243155451555010.1073/pnas.050658010216199517
     [Google Scholar]
  24. NewmanA.M. LiuC.L. GreenM.R. GentlesA.J. FengW. XuY. HoangC.D. DiehnM. AlizadehA.A. Robust enumeration of cell subsets from tissue expression profiles.Nat. Methods201512545345710.1038/nmeth.333725822800
     [Google Scholar]
  25. FuJ. LiK. ZhangW. WanC. ZhangJ. JiangP. LiuX.S. Large-scale public data reuse to model immunotherapy response and resistance.Genome Med.20201212110.1186/s13073‑020‑0721‑z32102694
     [Google Scholar]
  26. MaeserD. GruenerR.F. HuangR.S. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data.Brief. Bioinform.2021226bbab26010.1093/bib/bbab26034260682
     [Google Scholar]
  27. LyuG. LiD. XiongH. XiaoL. TongJ. NingC. WangP. LiS. Quantitative proteomic analyses identify STO/BBX24 -related proteins induced by UV-B.Int. J. Mol. Sci.2020217249610.3390/ijms2107249632260266
     [Google Scholar]
  28. DongbingL. GuizhenL. HongbinN. XiangW. JunY. A radish (Raphanus sativus L.) E3 ubiquitin ligase gene RHA2b enhances seed dormancy and tolerance to preharvest sprouting in transgenic wheat (Triticum aestivum L.).Appl. Ecol. Environ. Res.20191327313288
     [Google Scholar]
  29. LiD.B. LyuG. LyuJ. NiuH. WangX. Cloning and characterization of a wheat ring finger gene tarha2b whose expression is upregulated by aba treatment.Appl. Ecol. Environ. Res.20191747495751010.15666/aeer/1704_74957510
     [Google Scholar]
  30. ZhengJ. LiuC. ShiJ. WenK. WangX. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.Mol. Med. Rep.20212525310.3892/mmr.2021.1256934913077
     [Google Scholar]
  31. XiaoW. CaoR.C. YangW.J. TanJ.H. LiuR.Q. KanH.P. ZhouL. ZhangN. ChenZ.Y. ChenX.M. XuJ. ZhangG.W. ShenP. Roles and clinical significances of atf6, emc6, and apaf1 in prognosis of pancreatic cancer.Front. Genet.20221273084710.3389/fgene.2021.73084735222510
     [Google Scholar]
  32. ArefiniaN. RamezaniA. FarokhniaM. Arab ZadehA.M. YaghobiR. SarvariJ. Association between expression of ZBP1, AIM2, and MDA5 genes and severity of COVID-19.EXCLI J.2022211171118336320810
     [Google Scholar]
  33. QiangS. FuF. WangJ. DongC. Definition of immune molecular subtypes with distinct immune microenvironment, recurrence, and PANoptosis features to aid clinical therapeutic decision-making.Front. Genet.202213100710810.3389/fgene.2022.100710836313466
     [Google Scholar]
  34. WeiS. ChenZ. LingX. ZhangW. JiangL. Comprehensive analysis illustrating the role of PANoptosis-related genes in lung cancer based on bioinformatic algorithms and experiments.Front. Pharmacol.202314111522110.3389/fphar.2023.111522136874021
     [Google Scholar]
  35. WangX. SunR. ChanS. MengL. XuY. ZuoX. WangZ. HuX. HanQ. DaiL. BaiT. YuZ. WangM. YangW. ZhangH. ChenW. PANoptosis-based molecular clustering and prognostic signature predicts patient survival and immune landscape in colon cancer.Front. Genet.20221395535510.3389/fgene.2022.95535536186438
     [Google Scholar]
  36. HsuP.C. ChaoT.K. ChouY.C. YuM.H. WangY.C. LinY.H. LeeY.L. LiuL.C. ChangC.C. AIM2 inflammasome in tumor cells as a biomarker for predicting the treatment response to antiangiogenic therapy in epithelial ovarian cancer patients.J. Clin. Med.20211019452910.3390/jcm1019452934640548
     [Google Scholar]
  37. XiangY. ChenY.J. YanY.B. LiuY. QiuJ. TanR.Q. TianQ. GuanL. NiuS.S. XinH.W. MiR-186 bidirectionally regulates cisplatin sensitivity of ovarian cancer cells via suppressing targets PIK3R3 and PTEN and upregulating APAF1 expression.J. Cancer202011123446345310.7150/jca.4113532284740
     [Google Scholar]
  38. Au YeungC.L. CoN.N. TsurugaT. YeungT.L. KwanS.Y. LeungC.S. LiY. LuE.S. KwanK. WongK.K. SchmandtR. LuK.H. MokS.C. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.Nat. Commun.2016711115010.1038/ncomms1115027021436
     [Google Scholar]
  39. LiJ. LiQ. HuangH. LiY. LiL. HouW. YouZ. Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer.Int. J. Oncol.20175041087109610.3892/ijo.2017.389828350128
     [Google Scholar]
  40. LiuY. CaoH. ZhaoY. ShanL. LanS. Fisetin-induced cell death in human ovarian cancer cell lines via zbp1-mediated necroptosis.J. Ovarian Res.20221515710.1186/s13048‑022‑00984‑435538559
     [Google Scholar]
  41. ShiX. GaoX. LiuW. TangX. LiuJ. PanD. DuanX. JinY. RenW. YangL. LiuW. Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma.Oncol. Res.202331456959010.32604/or.2023.02896437415742
     [Google Scholar]
  42. JiangZ. WangJ. DaoC. ZhuM. LiY. LiuF. ZhaoY. LiJ. YangY. PanZ. Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.Apoptosis.2024295-668169210.1007/s10495‑023‑01932‑3
     [Google Scholar]
  43. WoutersM.C.A. NelsonB.H. Prognostic significance of tumor-infiltrating b cells and plasma cells in human cancer.Clin. Cancer Res.201824246125613510.1158/1078‑0432.CCR‑18‑148130049748
     [Google Scholar]
  44. CiavarellaS. VeglianteM.C. FabbriM. De SummaS. MelleF. MottaG. De IuliisV. OpintoG. EnjuanesA. RegaS. GulinoA. AgostinelliC. ScattoneA. TommasiS. MangiaA. MeleF. SimoneG. ZitoA.F. IngravalloG. VitoloU. ChiappellaA. TarellaC. GianniA.M. RambaldiA. ZinzaniP.L. CasadeiB. DerenziniE. LosetoG. PileriA. TabanelliV. FioriS. Rivas-DelgadoA. López-GuillermoA. VenesioT. SapinoA. CampoE. TripodoC. GuariniA. PileriS.A. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.Ann. Oncol.20193012201510.1093/annonc/mdz38631539020
     [Google Scholar]
  45. LinX. YeL. WangX. LiaoZ. DongJ. YangY. ZhangR. LiH. LiP. DingL. LiT. ZhangW. XuS. HanX. XuH. WangW. GaoH. YuX. LiuL. Follicular helper t cells remodel the immune microenvironment of pancreatic cancer via secreting CXCL13 and IL-21.Cancers (Basel)20211315367810.3390/cancers1315367834359579
     [Google Scholar]
  46. LiuX. WuS. YangY. ZhaoM. ZhuG. HouZ. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer.Biomed. pharmacoth.201795556110.1016/j.biopha.2017.08.003
     [Google Scholar]
  47. HanY. ShiY. ChenB. WangJ. LiuY. ShengS. FuZ. ShenC. WangX. YinS. LiH. An ion-channel-gene-based prediction model for head and neck squamous cell carcinoma: Prognostic assessment and treatment guidance.Front. Immunol.20221396169510.3389/fimmu.2022.96169536389709
     [Google Scholar]
  48. MaioranoB.A. MaioranoM.F.P. LorussoD. MaielloE. Ovarian cancer in the era of immune checkpoint inhibitors: State of the art and future perspectives.Cancers (Basel)20211317443810.3390/cancers1317443834503248
     [Google Scholar]
  49. YangC. XiaB.R. ZhangZ.C. ZhangY.J. LouG. JinW.L. Immunotherapy for ovarian cancer: Adjuvant, combination, and neoadjuvant.Front. Immunol.20201157786910.3389/fimmu.2020.57786933123161
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673314864240829064622
Loading
Construction of a PANoptosis-related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Ovarian Cancer
Curr. Med. Chem. 32, 7840 (2025); https://doi.org/10.2174/0109298673314864240829064622
/content/journals/cmc/10.2174/0109298673314864240829064622
/content/journals/cmc/10.2174/0109298673314864240829064622
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): immune response; Ovarian cancer; PANoptosis; PRG signature; prognosis; tumor microenvironment

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test